#Long QT Syndrome Size | Explore Tumblr posts and blogs

blog-site-for-market-research · 9 months ago

Text

Forecasting the Size of Long QT Syndrome Market

Market Overview –

The long QT syndrome market is anticipated to grow at a 5.2% CAGR from 2022 to 2030, or USD 3,933.02 million.

The Long QT Syndrome (LQTS) market encompasses medical interventions and devices designed to diagnose, treat, and manage this cardiac disorder characterized by abnormal heart rhythms. LQTS increases the risk of sudden cardiac arrest or arrhythmias, posing serious health threats. The market includes genetic testing, medications, implantable cardioverter-defibrillators (ICDs), and lifestyle modifications aimed at reducing the risk of life-threatening events.

The Long QT Syndrome market is characterized by advancements in understanding and managing this cardiac disorder. With a focus on long QT disorder, healthcare providers emphasize early diagnosis and personalized treatment approaches to mitigate the risk of life-threatening arrhythmias. As awareness grows, there's a rising demand for innovative therapies and genetic testing, driving market growth and research endeavors.

A key driver of the Long QT Syndrome market is the growing awareness of inherited cardiac disorders and advances in genetic testing technology. Early detection through genetic screening allows for timely interventions, such as medication adjustments or implantation of ICDs, to prevent cardiac events and improve patient outcomes.

Advancements in medical devices, such as miniaturized ICDs and wearable cardiac monitors, have revolutionized the management of Long QT Syndrome. These devices provide continuous monitoring and early detection of arrhythmias, offering peace of mind to patients and caregivers while improving overall safety.

The COVID-19 pandemic has impacted the Long QT Syndrome market, with disruptions in routine medical care, delayed diagnoses, and challenges in accessing specialized cardiac services. However, telemedicine and remote monitoring technologies have emerged as valuable tools in managing Long QT Syndrome, enabling patients to receive timely care and support from healthcare providers.

Segmentation –

The global long QT syndrome market is segmented on the basis of type, diagnosis, treatment, and end users. On the basis of the type, the market is segmented into long QT syndrome type 1, long QT syndrome type 2, long QT syndrome type 3, and others. On the basis of the diagnosis, the market is categorized into tests, electrocardiogram (ECG), genetic testing, and others.

On the basis of the treatment, the market is segmented into medication, surgical procedures, and others. On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic labs, research organizations, and others.

Regional Analysis –

Regional analysis of the Long QT Syndrome (LQTS) market reveals variations in diagnosis rates, treatment options, and healthcare infrastructure across different regions. In developed regions like North America and Europe, where there is greater awareness of genetic disorders and access to specialized cardiac care, the market for LQTS diagnostics and management is well-established, with genetic testing, beta-blockers, and implantable cardioverter-defibrillators (ICDs) being standard of care.

Conversely, in developing regions with limited access to advanced cardiac diagnostics and therapies, such as parts of Africa and Asia-Pacific, the market for LQTS is still emerging, with challenges related to underdiagnosis and limited treatment options. Moreover, cultural attitudes towards genetic testing and preventive healthcare influence patient behaviors and healthcare-seeking patterns across different regions. As awareness of LQTS and its genetic basis increases globally, there is a growing opportunity for market expansion through education, advocacy, and investment in cardiac care infrastructure to improve outcomes for LQTS patients worldwide.

Key Players –

Long QT syndrome key players include Invitae Corporation (U.S.), GeneDx (U.S.), Asper Biogene (Estonia), Boston Scientific Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), Pfizer Inc. (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Aralez Pharmaceuticals Inc. (Canada), AstraZeneca (U.K.), Torrent Pharmaceuticals Limited (India), Lupin Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), and others.

Related Reports –

Pain Patch

Electronic Trial Master File Systems

Neurology Devices

Medical Payment Fraud Detection

For more information visit at MarketResearchFuture

#Long QT Syndrome #Long QT Syndrome Size #Long QT Syndrome Share #Long QT Syndrome Growth #Long QT Syndrome Trends

0 notes

meret118 · 1 year ago

Text

college student with a heart condition, Sarah Katz, died after drinking a heavily-caffeinated drink from Panera; her parents assert in the suit that Katz likely thought the beverage would be safe to drink because the chain’s marketing of the product does not reflect its high caffeine content.

The large size of Panera’s large Charged Lemonade, per the New York Times, has more caffeine than a 12-ounce Red Bull and a 16-ounce Monster Energy Drink combined. However, it is advertised as being “clean.” Katz had Long QT Type 1 Syndrome, a heart condition that necessitated avoiding highly caffeinated beverages. “If she didn’t know that this was an energy drink, it makes the family concerned about who else doesn’t know,” Elizabeth Crawford, the Katz fa

4 notes · View notes

omkarpatel · 9 months ago

Text

Cardiac Implants: A Revolution in Treating Heart Conditions

Cardiac care has seen tremendous advancement over the past few decades. From open-heart surgeries to minimally invasive procedures, the medical field has come a long way in effectively diagnosing and treating various heart diseases. One area that has seen significant progress is the use of cardiac implants - medical devices that are either implanted inside or on the surface of the body to treat and monitor heart conditions. These implants have revolutionized the management of cardiac disease and improved quality of life for millions of patients worldwide. Pacemakers: Lifesaving Devices for Irregular Heartbeats One of the most commonly used cardiac implants is the pacemaker. Pacemakers are small devices, about the size of a matchbox, that are implanted underneath the skin of the chest to help regulate abnormal heart rhythms. They work by delivering low-voltage electrical pulses to prompt the heart's natural pacemaker - the sinoatrial node - to beat at a normal rate when it is too slow. Pacemakers are used to treat bradycardia, a condition where the heart beats too slowly, irregularly, ornot strongly enough to pump enough blood to the body. They can dramatically reduce symptoms of fatigue and dizziness caused by slow heart rates. Modern pacemakers come with sophisticated sensors and programming options that allow them to adapt to different heart conditions and activity levels. Some can even communicate wirelessly with programming devices, allowing remote monitoring of the device and heart health. Besides traditional single and dual-chamber devices, there are also biventricular pacemakers that coordinate the lower chambers of the heart for more effective pumping in heart failure patients. Pacemakers have saved millions of lives over 50 years and remain one of the most effective cardiac implants available today. Defibrillators: Lifesavers for Lethal Heart Rhythms For patients at high risk of potentially fatal heart rhythms called ventricular tachycardias or fibrillation, implantable cardioverter-defibrillators or ICDs provide lifesaving protection. These devices continuously monitor the heart for abnormal rhythms and can deliver high-energy electrical shocks to the heart to restore normal rhythm when detected. ICDs have not only reduced mortality in high-risk patients but also improved quality of life by terminating dangerous arrhythmias before they become life-threatening. Similar to pacemakers, ICDs have also become more sophisticated with remote monitoring capabilities, better detection algorithms, and multi-chamber coordination. Subcutaneous ICDs that sit just under the skin and have no leads inside the heart are being used in some cases to avoid potential lead complications. While ICDs carry some risk of repeated shocks, they are remarkably effective as the first line of defense against sudden cardiac death in many patients with structural heart disease or genetic conditions causing lethal arrhythmias like long QT syndrome

#healthcare

0 notes

tx-hospital · 1 year ago

Text

Implantable Cardioverter Defibrillators (ICDs): Lifesaving Devices for Cardiac Arrhythmias

An Implantable Cardioverter Defibrillator (ICD) is a sophisticated medical device designed to monitor and treat life-threatening cardiac arrhythmias. It is a crucial tool in the management of various heart conditions, particularly those at risk of sudden cardiac death.

Indications for ICD Implantation:

Ventricular Tachycardia (VT): ICDs are often recommended for patients with sustained VT or ventricular fibrillation (VF), as these arrhythmias can be fatal without prompt intervention.

Previous Cardiac Arrest: Individuals who have survived a sudden cardiac arrest or who are at high risk of recurrence may benefit from an ICD.

Heart Failure: In some cases of heart failure, especially when it's associated with reduced ejection fraction, ICDs can help prevent arrhythmia-related complications.

Long QT Syndrome and Other Genetic Arrhythmia Syndromes: Patients with certain inherited arrhythmia syndromes may receive an ICD to prevent life-threatening events.

Components of an ICD:

Pulse Generator: This small device, similar in size to a pager, contains the battery and electronic circuitry. It is implanted under the skin, typically near the collarbone.

Leads: Thin, insulated wires connect the pulse generator to the heart. There are usually one or more leads, depending on the specific device and patient needs. Leads monitor the heart's electrical activity and deliver therapies when needed.

How ICDs Work:

Continuous Monitoring: ICDs continuously monitor the heart's electrical activity, looking for abnormal rhythms.

Detection: When a life-threatening arrhythmia is detected (such as VT or VF), the ICD delivers an electrical shock to restore the heart's normal rhythm. This is known as defibrillation.

Antitachycardia Pacing (ATP): In some cases, the device may use pacing to correct certain arrhythmias without delivering a shock.

Bradycardia Pacing: Many ICDs also function as pacemakers, providing pacing support to prevent slow heart rates (bradycardia).

ICD Implantation Procedure:

Anesthesia: The procedure is typically performed under local anesthesia with sedation, allowing the patient to remain awake but relaxed.

Device Placement: A small incision is made near the collarbone, and the pulse generator is implanted under the skin. Leads are threaded through veins and positioned in the heart.

Testing: The device is tested to ensure proper function and accurate sensing of heart rhythms.

Closure: The incision is closed with sutures or adhesive, and a sterile dressing is applied.

Risks and Complications:

Infection Bleeding Lead problems (e.g., dislodgment) Device-related complications (e.g., battery depletion)

REFERENCE:

TX Hospitals Group in Hyderabad is one of the country’s largest and fastest-growing chains of multi-super specialty hospitals.

CONTACT : 9089489089

BOOK APPOINTMENT NOW with the Best Doctors in Hyderabad.

Facebook

Twitter

Instagram

YouTube

#tx hospitals #best treatment in hyderabad #ICD Surgery #ICD surgery in Hyderabad

0 notes

drramjimehrotra · 1 year ago

Text

(Dr Ramji Mehrotra) What are Inherited Cardiac Conditions?

Inherited cardiac conditions are a group of cardiovascular disorders that are caused by genetic mutations or abnormalities passed down from parents to their children. These conditions can affect the structure or function of the heart and may occur at various stages of life, from infancy to adulthood. Understanding the nature of inherited cardiac conditions is crucial for early detection, proper management, and preventive measures.

One prominent example of an inherited cardiac condition is hypertrophic cardiomyopathy (HCM). HCM is characterized by the thickening of the heart muscle, particularly in the left ventricle. This abnormal thickening can disrupt the heart's pumping ability and lead to symptoms such as chest pain, shortness of breath, and palpitations. In some cases, HCM can cause sudden cardiac arrest, especially during intense physical activity.

According to Dr. Ramji Mehrotra, leading cardiac surgeon in NCR region, genetic mutations in genes responsible for the structure of cardiac muscle proteins are often associated with HCM. Diagnosis typically involves a combination of clinical evaluation, imaging tests like echocardiography, and genetic testing to identify specific mutations. Management may include medications to alleviate symptoms, lifestyle modifications, and, in severe cases, surgical interventions.

Another inherited cardiac condition is Long QT syndrome (LQTS), which affects the electrical system of the heart. Individuals with LQTS have an abnormality in the ion channels responsible for regulating the heart's electrical activity. This can lead to irregular and potentially life-threatening arrhythmias, including a specific type known as Torsades de Pointes.

Symptoms of LQTS may include fainting, seizures, and sudden cardiac arrest. Genetic testing can identify mutations associated with LQTS, and electrocardiograms (ECGs) are used to evaluate the heart's electrical activity. Treatment typically involves medications to prevent arrhythmias, lifestyle modifications, and the avoidance of certain medications that can prolong the QT interval.

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac condition that affects the structure and function of the heart's right ventricle. In ARVC, the normal muscle tissue in the right ventricle is progressively replaced by fatty or fibrous tissue, leading to abnormal heart rhythms and, in some cases, heart failure. Genetic mutations involving proteins responsible for maintaining the structural integrity of heart cells are often associated with ARVC. Diagnosis may involve a combination of clinical evaluation, imaging tests like cardiac MRI, and genetic testing. Treatment typically focuses on managing arrhythmias, preventing sudden cardiac death, and addressing heart failure symptoms through medications, implantable devices like defibrillators, and lifestyle modifications.

Marfan syndrome is an inherited connective tissue disorder that can also affect the cardiovascular system. It is caused by mutations in the FBN1 gene, which leads to abnormalities in the production of the protein fibrillin-1. Fibrillin-1 is a crucial component of connective tissue that provides strength and elasticity to various structures, including the heart's valves and aorta.

In individuals with Marfan syndrome, the aorta can be weakened and dilated, increasing the risk of aortic dissection or rupture. Diagnosis involves clinical evaluation, imaging tests like echocardiography, and genetic testing to confirm the presence of FBN1 mutations. Treatment may include medications to manage symptoms, regular monitoring of the aorta's size, and surgical interventions to repair or replace the affected valves or aorta if necessary.

Dr. Ramji Mehrotra says that understanding the genetic basis of inherited cardiac conditions, along with appropriate diagnostic strategies and management approaches, is crucial for early detection, prevention of complications, and optimal care.

0 notes

lawful-evil-novelist · 5 years ago

Note

My baby Jervis Tetch!!! Also you've mentioned him a few times and I'm curious on the different ways Roman Sionis grew up? (Sorry I spelled Soinis wrong)

No, no, it’s Sionis. But I’ll gladly talk about....these very different men are you aware these are very different personalities?

CW on Roman’s end for mentions of abuse.

Anyway on November 26, 1979, Jervis Tetch was born in St. Austell, England, stopped growing or aging at age 12, and somehow managed to walk out of university with a biological engineering degree and a host of terrible ideas.

There isn’t much about Jervis’ upbringing or early life that’s remarkable, that’s kind of the creepy part. Aside from when he was 17 and doctors diagnosed him with schizoaffective disorder, for which he was medicated. Jervis is kind of scatter-brained, so his regularity with taking his medication is all over the place, and therein lies the problem.

So, you probably think during one of these bouts of not being medicated, Jervis decided he needed an Alice and that he was the Mad Hatter. NO. Actually, Jervis decided he was the Mad Hatter and that he needed to throw a tea party. His guests? Jonathan Crane and Edward Nygma, who he mind controlled into a warehouse and promptly drugged so the sufficiently acted like the March Hare and the Dormouse. His Alice obsession didn’t come until like, a year later. Jon and Ed aren’t mad at Jervis, but they ain’t happy with him about that stunt.

Roman Sionis, or Roman Seung as he’s legally named, was born in Gotham on April 15, 1985. He was born into a pretty infamous crime syndicate that bears his Korean surname. When Roman was three, his mother made him get surgery so he had a double eyelid (he was born with a monolid). Roman, to this day, doesn’t know he’s had work done on his eyes, his mother never told him.

Anyway, when he was young Roman was diagnosed with Long QT Syndrome and was given a pacemaker to cope with it. His father wasn’t really happy that Roman was already showing medical problems and promptly blamed Roman’s mother. Roman grew up with a lot of fighting around him. Roman’s mother taught him to use his smaller size and pretty face to his advantage, while his father taught him to run a criminal organization and a front business. Roman excelled at both, but it didn’t stop either parent from physically and emotionally abusing Roman any chance they could get. Though initially forced to befriend them, Roman became very close with Bruce Wayne and Harvey Dent, to the point where he currently lets Harvey get away with shit he’d shoot any other rogue for doing.

When Roman was about 15, his mother made him go into modelling, which he was also quite good at. Roman was still modelling when Neil Richards, then 15, started designing, but he stopped soon after. He still does modeling for Neil on occasion because Neil is really nice to his models.

Roman’s father was killed by his mother when he was 19, or at least, that’s how the media frames it. In reality, Roman killed his father and framed his mother for the crime. To avoid the negative press his father got for running a syndicate, Roman ran his criminal operations while wearing a black mask resembling a Japanese Oni mask. Roman calls this misdirection, I call it being a little shit. Regardless of the proper name, for it, Roman’s mask did not stop Batman from figuring out who he was, but in fairness Batman’s mask didn’t stop Roman either so there’s that.

#jervis tetch #mad hatter #the mad hatter #roman sionis #black mask #lawfulverse #asks #answered #themarchinghare

14 notes · View notes

marketreports-world · 3 years ago

Link

#Long QT Syndrome Market

0 notes

techscimarketresearch · 3 years ago

Text

United States Pacemaker Market to Register Healthy Growth through 2025 | TechSci Research

Increasing cases of cardiovascular diseases and technological advancements in healthcare to drive United States pacemaker market.

According to TechSci Research report, “United States Pacemaker Market By Type (MRI Compatible Pacemakers, Conventional Pacemakers), By Product Type (Implantable Pacemaker, External Pacemaker), By Application (Heart Block, Arrhythmia, Atrial Fibrillation, Bradycardia, Tachycardia, Long QT Syndrome), By Technology (Single Chamber, Dual Chamber, CRT-P/Biventricular Pacemaker), By End User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025”, the market is anticipated to grow at a significant CAGR during the forecast period. Key factors propelling the growth of United States pacemaker market include increasing prevalence of cardiovascular diseases and the spread of COVID-19, which has led to high spread of CVDs among patients suffering from coronavirus. The increasing demand for minimally invasive procedures is also creating high demand for pacemakers in United States market. Furthermore, technological advancements and launch of new products such as leadless pacemakers and MRI safe pacemakers are expected to propel the market growth in coming years. Also, favorable government policies and increasing expenditure on healthcare sector are supporting the growth of United States pacemaker market.

Additionally, favorable reimbursement procedures such as Medicare system coupled with rise in manufacturing high-end pacemakers, which caters to customized care are fueling the growth of United States pacemaker market. Along with this, growing geriatric population who are more vulnerable to cardiovascular diseases is also acting as a major growth driver for this market. The advent of battery free pacemakers has brough revolutionary change in the market and is augmenting the market growth. With increasing FDA approval for novel pacemakers, the market is expected to witness substantial growth through 2025. However, pacemaker devices cost two to six times more in the United States than in European countries such as Germany. This might hinder the United States pacemaker market growth.

Browse XX market data Tables and XX Figures spread through XX Pages and an in-depth TOC on "United States Pacemaker Market"

https://www.techsciresearch.com/report/united-states-pacemaker-market/5173.html

The United States pacemaker market is segmented based on type, product type, application, technology, end user and region. Based on application, the market can be segmented into heart block, arrhythmia, atrial fibrillation, bradycardia, tachycardia, and long QT syndrome. Among them, atrial fibrillation is expected to hold a significant share in United States pacemaker market during the forecast period. According to CDC, around 2.7–6.1 million people in the United States have atrial fibrillation, which is the most common type of heart arrhythmia. The number is expected to increase over the coming years.

Based on technology, United States pacemaker market can be segmented into single chamber, dual chamber, and CRT-P/biventricular pacemakers. Among them, dual-chamber pacemakers held significant share in United States market in 2019, owing to reduced post-surgical complications and presence of two leads which assure normal physiology of the heart. However, CRT-P, also known as biventricular pacemakers, are expected to register fastest growth in United States pacemaker market during the forecast period as they are increasingly being used to treat people with arrhythmias caused by advanced heart failure. These pacemakers contain three leads which are connected to the right atrium and both ventricles.

Major players operating in the United States pacemaker market include Biotronik, Inc., Boston Scientific Corporation, Abbot Inc., Zoll Medical Corporation, Oscor Inc., Medtronic, Inc., Cordis, Inc., Livanova PLC, Medico Inc., Oscor Inc. and Osypka Medical Inc. Leading companies are undertaking growth strategies such as new product launches, mergers & acquisitions, and partnerships.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5173

Customers can also request for 10% free customization on this report.

“The introduction of U.S. Food and Drug Administration (FDA)-cleared MRI-conditional pacemaker models are a growing trend in United States. Around 20% of pacemaker patients need an MRI within the first two years of implant. Pacemakers which do not have MRI-conditional use technology, generally prevent patients from being able to get an MRI. With increasing cases of cardiovascular diseases in the country, more manufacturers are coming up with advanced products and are using MRI-conditional use technology,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Pacemaker Market By Type (MRI Compatible Pacemakers, Conventional Pacemakers), By Product Type (Implantable Pacemaker, External Pacemaker), By Application (Heart Block, Arrhythmia, Atrial Fibrillation, Bradycardia, Tachycardia, Long QT Syndrome), By Technology (Single Chamber, Dual Chamber, CRT-P/Biventricular Pacemaker), By End User (Hospitals & Cardiac Centers, Ambulatory Surgical Centers), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of United States pacemaker market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States pacemaker market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #United States Pacemaker Market #Healthcare #Pacemaker Market #US Pacemaker Market Size #Medical Devices #US Pacemaker Market Forecast

0 notes

techsciresearch · 3 years ago

Text

United States Pacemaker Market to Register Healthy Growth through 2025 | TechSci Research

Increasing cases of cardiovascular diseases and technological advancements in healthcare to drive United States pacemaker market.

Browse XX market data Tables and XX Figures spread through XX Pages and an in-depth TOC on "United States Pacemaker Market"

https://www.techsciresearch.com/report/united-states-pacemaker-market/5173.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5173

Customers can also request for 10% free customization on this report.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #United States Pacemaker Market #Healthcare #Medical Devices #US Pacemaker Market Forecast #Pacemaker Market #US Pacemaker Market Size

0 notes

market-research-future · 3 years ago

Text

Long QT Syndrome Market Overview, Economic Impact, Dynamics and SWOT Analysis To 2027

Market Highlights

The market of Long QT syndrome (LQTS) is driven by factors like the prevalence of cardiovascular diseases & diabetes, and growing geriatric population. Moreover, rising per capita healthcare expenditure and increasing R&D expenses by the key players is fuelling the market growth over the forecast period. However, lack of awareness and stringent FDA approvals followed by the high cost of the surgical therapeutics pertaining to this disorder are restraining the market growth.

The global long QT syndrome market is expected to grow at a CAGR of 8.50% during the forecast period.

Segmentation

Regional Analysis

The Americas dominate the global long QT syndrome market. A well-developed healthcare sector, high per capita healthcare expenditures, increasing number of patients suffering from cardiovascular diseases and diabetes are the major drivers for long QT syndrome market in the Americas. Moreover, the presence of developed economies like the U.S. and Canada boosts the market growth within this region.

Europe holds the second largest market share. Availability of funds for research, huge patient population, and government support for research & development will drive the market. Regionally, Europe is divided into Western Europe and Eastern Europe. The Western Europe leads the market within the Europe. However, Eastern Europe is estimated to be the fastest growing region.

Browse Full Report @ https://www.marketresearchfuture.com/reports/long-qt-syndrome-market-5303 .

Asia Pacific is the fastest growing market. Increasing prevalence of diabetes and growing geriatric population are the major driving factors for the market growth within the region. Moreover, the presence of developing healthcare sector and developing economies within the region are boosting the market growth.

The Middle East & Africa holds the least share of the market. Presence of poor economies and stringent government policies especially in the Africa region are the restraining factors for market growth within the region. The Middle East holds a major share of the market within the region. This can be attributed due to huge healthcare expenditures by the developed economies of the region.

Key Players

The key players for the global long QT syndrome market are Invitae Corporation (U.S.), GeneDx. (U.S.), Asper Biogene (Estonia), Boston Scientific Corporation (U.S.), Laboratory Corporation of America Holdings (U.S.), Pfizer Inc. (U.S.), Zydus Pharmaceuticals, Inc. (U.S.), Aralez Pharmaceuticals Inc. (Canada), AstraZeneca (U.K), Torrent Pharmaceuticals Limited (India), Lupin Pharmaceuticals, Inc. (U.S.), Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), and others.

Browse Related Reports at:

Telehealth Market Trends, Size, Growth, Share, Application and Analysis by 2024 | MRFR

Migraine Drugs Market by Type, Drug Class, Growth Analysis Till 2027 | MRFR

Patient Registry Software Market Size, Share, Type, Global Analysis, 2027 | MRFR

0 notes

sumit76652-blog · 6 years ago

Text

Implantable Cardiac Pacemaker Market - Global Forecast to 2026

Implantable cardiac pacemaker is a small device implanted in the chest or abdomen for the treatment of abnormal heart rhythms, arrhythmia, heart block, and atrial fibrillation. Implantable cardiac pacemaker is evolved from battery-powered transistorized wearable pacemakers to current leadless pacemaker, an entire pacemaker which is placed within cardiac chambers. Cardiac pacemakers are used to treat abnormal electrical signaling in the heart, which causes arrhythmias. Implantable cardiac pacemaker use low-energy electrical signals to speed up the slow heartbeat, help to control an abnormal and fast heart rhythm, and prevents long QT syndrome, a disorder of the heart’s electrical activity, which causes sudden, uncontrollable, and dangerous arrhythmias.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1663

Market Dynamics

Market players are engaged in developing novel pacemakers with ability to control the abnormal heart rhythm, monitor and record patient’s heart's electrical activity, blood temperature, and breathing rate. Technological advances in the field of implantable cardiac pacemakers along with increasing prevalence of cardiovascular disease is projected to drive the growth of implantable cardiac pacemaker market over the forecast period.

Introduction of Advanced Pacemaker Technologies is Expected to Drive Growth of the Implantable Cardiac Pacemaker Market

Adoption of advanced technologies in cardiac pacemakers such as MRI safe-pacemakers, pacemakers with improved battery life, delay the progression of persistent Atrial Fibrillation (AF) in patients suffering from bradycardia and wireless automated technologies. This advancements are gaining significant traction of various market players of implantable cardiac pacemakers with affordable costs, which in turn are expected to drive growth of implantable cardiac pacemakers market. For instance, in February 2017, Abbott received the Food and Drug Administration (FDA) approval for its MR-conditional labeling for both of its products i.e. Assurity MRI pacemaker and the Tendril MRI pacing lead. Furthermore, introduction of advance technology such as wireless and automated pacemaker monitoring pacemakers are gaining significant traction among healthcare providers.

For instance, in 2016, Biotronik launched CardioMessenger Smart, portable monitoring device in the U.S. This system is about the size of a modern smartphone used to keep pacemaker, Implantable Cardioverter Defibrillator (ICD) and Insertable Cardiac Monitor (ICM) patients connected to their physician remotely. This CardioMessenger Smart helps to ensure patient compliance and the consistent transmission of data necessary for physicians to identify and prevent potential cardiac events. Thus, such wireless technologies are gaining traction of vendors, which is expected to drive the growth of the implantable cardiac pacemaker market

Increasing Prevalence of Cardiovascular Disease is Expected to Drive Growth of Implantable Cardiac Pacemaker Market

Increasing incidence of cardiovascular diseases is expected to boost growth of the implantable cardiac pacemakers market over the forecast period. According to the Centers for Disease Control and Prevention (CDC), August 2017 data findings, Atrial Fibrillation (AFib or AF) is most common type of heart arrhythmia, which affected an estimated 2.7 to 6.1 million people in the U.S. and the number is expected to increase in near future. Furthermore, Atrial Fibrillation cases increase with age and it is more prominent in men than women. Moreover, increasing number of geriatric population across the various regions worldwide along with high prevalence of heart disease is expected to propel demand for implantable cardiac pacemakers in the near future.

However, implantable pacemakers associated infections in cardiac patients is hindering growth of the implantable cardiac pacemaker market. Pacemaker surgery is associated with swelling, bruising, bleeding, or infection of the area where the pacemaker was placed leading to blood vessel or nerve damage and adverse reaction of medicine used during the pacemaker implantation surgery, which may reduce the adoption of implantable cardiac implants in patients.

For More Information @ https://www.coherentmarketinsights.com/market-insight/implantable-cardiac-pacemaker-market-1663

Global Key Players:

Some of the key players operating in implantable cardiac pacemaker market include Medtronic plc, BIOTRONIK, Inc., Boston Scientific Corporation, St. Jude Medical, Vitatron Holding B.V., Shree Pacetronix Ltd., MEDICO S.p.A., Lepu Medical Technology Co Ltd., LivaNova PLC, and Qinming Medical.

Detailed Segmentation:

Global Implantable Cardiac Pacemaker Market, By Product Type:

Single Chamber Pacemaker

Dual Chamber Pacemaker

Biventricular Pacemaker

Global Implantable Cardiac Pacemaker Market, By Application:

Heart Block

Arrhythmia

Atrial fibrillation

Long QT Syndrome

Bradycardia

Tachycardia

Others

Global Implantable Cardiac Pacemaker Market, By End User:

Hospitals

Emergency Care Centers

Others

Global Implantable Cardiac Pacemaker Market, By Region:

North America

Europe

Asia Pacific

Middle East

Latin America

Africa

Request For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1663

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: [email protected]

0 notes

kraftresearch2019 · 5 years ago

Text

Long QT Syndrome Treatment Market Size, Industry Survey, Competitive Trends, Outlook and Forecasts 2019 to 2024

The report supplies a holistic summary of this global Long QT Syndrome Treatment market 2019 -2024 with the assistance of application segments and leading geographic regions that regulate the industry currently.

The Long QT Syndrome Treatment report 2018 supplies a comprehensive and skilled study on the state of the worldwide industry together with sales forecast and landscape, and share 2024. The Long QT Syndrome Treatment analysis introduced the fundamentals: product specifications, applications, and industry review; industry policies and plans; definitions; fabricating procedures; cost arrangements, and so forth.

Subsequently it studies the crucial global region requirements, for example, price, profit, capacity, production, capacity use, distribution, demand and industry development speed, etc. The Long QT Syndrome Treatment report introduced analysis, investment feasibility, and SWOT analysis. Meanwhile, the chief search is performed connected to the conveyance region, station, and product types, with the key application.

Access Exclusive Free Sample Report at: https://www.researchkraft.com/request-sample/953206

Competitive Analysis:

Our research analysts also have taken significant account facets and landscape scenario like Long QT Syndrome Treatment industry market placement plan frame, and competitive atmosphere for providing a competitive analysis. For company profiling, product analysis, initiatives, and operation of players.

These Players are covered in this Report:

Boston Scientific, Cadila Healthcare, Pfizer, AstraZeneca, Lupin Pharmaceuticals, Cipla, Mylan, Teva Pharmaceutical, Old API Wind-Down, Torrent Pharmaceuticals

Long QT Syndrome Treatment Market Based on Types:

Medication

Surgery Therapy

Long QT Syndrome Treatment Market Based on Applications:

Hospitals

Clinics

Others

Get it in Discounted Price: https://www.researchkraft.com/check-discount/953206

Market Segment by Regional analysis ensures:

Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey, GCC Countries

Our report provides:

Global Long QT Syndrome Treatment Market share evaluations for regional and country level sections; Market share analysis of the industry players;

Present tips to the newest entrants;

Market predictions by 2025 of the mentioned the niches, sub-sections along with sections;

Economy Trends (Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and Tips);

Tactical tips in key Long QT Syndrome Treatment industry segments centered in the market estimations;

Aggressive landscaping mapping is the main element global Long QT Syndrome Treatment market trends that are prevalent;

Company profiling with financials, plans, and recent advancements; Supply series trends mapping technological advances;

Any Query? Ask Our Expert at: https://www.researchkraft.com/send-an-enquiry/953206

Customization of this Report: This Long QT Syndrome Treatment report could be customized to the customer's requirements. Please contact our sales professional ([email protected]), we will ensure you obtain the report which works for your needs.

#Long QT Syndrome Treatment Long QT Syndrome Treatment Market Long QT Syndrome Treatment Market Size Long QT Syndrome Treatment Industry Long

0 notes

thesittingduck · 4 years ago

Text

diprostene injection Uses, Dosage, Side Effects & Precautions

Drug Online

diprostene injection in english >> Generic drug of the Therapeutic class: Anti-inflammatory active ingredients: Betamethasone

what is Diprostene ampoule ?

This medication is a corticosteroid.

It is indicated in cases of allergic rhinitis.

It can be used in local injection in dermatology, rheumatology and ENT.

what is Diprostene injection uses and indication?

SYSTEMIC USE

Seasonal allergic rhinitis after failure of other therapies (systemic antihistamine, intranasal corticosteroid, or oral corticosteroid in short course).

LOCAL USE

These are those of local corticosteroid therapy, when the affection justifies a strong local concentration. Any local injection prescription must take account of the infectious danger, in particular the risk of promoting bacterial proliferation.

This product is indicated in the conditions:

Skin: keloid scars

ENT: intra-sinus irrigation in sinusitis subacute or chronic justifying drainage.

Rheumatologic:

intra-articular injections: inflammatory arthritis, severe arthritis

periarticular injections: tendonitis, bursitis

soft tissue injections: talalgia, carpal tunnel syndrome, Dupuytren’s disease

PRESENTATION (S) AVAILABLE FOR DIPROSTENE

1 pre-filled syringe (s) of 1 ml glass with needle (s)

FEATURE DESCRIPTION Pharmaceutical class systemic corticosteroids Active substance (s) for 1 ml of suspension for injection: betamethasone (disodium phosphate) (2.63 mg), betamethasone dipropionate (6.43 mg) General medicine no Pharmaceutical form suspension for injection Route (s) of administration endosinus, intra-articular, intralesional, intramuscular, periarticular Social security reimbursement rate 65% Laboratory (s) MSD FRANCE Conditions of issue available by simple prescription

Diprostene Dosage

The dose to use is determined by your doctor, depending on your weight and the disease being treated.

It is strictly individual.

Diprostene Contraindications

INTRAMUSCULAR USE

Never use DIPROSTENE, suspension for injection in a pre-filled syringe in the following cases:

in premature and term newborns, due to the presence of benzyl alcohol,

most infections,

certain evolving viral diseases (viral hepatitis, herpes, chickenpox, shingles),

certain untreated mental disorders,

vaccination with live vaccines,

allergy to one of the constituents,

coagulation disorders, anticoagulant therapy in progress.

This medication SHOULD NOT GENERALLY BE USED, unless your doctor advises otherwise, in combination with medications which may cause certain heart rhythm disturbances.

LOCAL USE

Never use DIPROSTENE, suspension for injection in a pre-filled syringe in the following cases:

infections,

allergy to one of the constituents,

coagulation disorders, current anticoagulant treatment,

in premature and term newborns, due to the presence of benzyl alcohol.

IN CASE OF DOUBT, IT IS ESSENTIAL TO ASK FOR THE OPINION OF YOUR DOCTOR OR YOUR PHARMACIST.

How To Take Diprostene ?

Method and route of administration

INTRAMUSCULAR INJECTABLE OR LOCAL INJECTION.

Do not inject into the tendons.

Duration of treatment

It is determined by your doctor.

how does Diprostene work?

Pharmacotherapeutic group: corticosteroids for systemic use, not associated, ATC code: H02AB01 .

Physiological glucocorticoids (cortisone and hydrocortisone) are essential metabolic hormones.

Synthetic corticosteroids, including betamethasone, are used primarily for their anti-inflammatory effect.

In high doses, they decrease the immune response. Their metabolic and sodium retention effect is less than that of hydrocortisone.

How To Store Diprostene ?

Keep this medication out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the package after EXP. The expiration date refers to the last day of that month.

Store at a temperature not exceeding 25 ° C and protected from light.

After opening: the product should be used immediately.

Do not throw away any medicines via a wastewater treatment plant or with household waste. Ask your pharmacist how to throw away the medicines you no longer use. These measures will help protect the environment.

Diprostene injection side effects

Like all medicines, DIPROSTENE, suspension for injection in a pre-filled syringe can cause side effects, although not everybody gets them.

INTRAMUSCULAR USE

This essential drug is most often well tolerated when following the recommendations and especially the diet. However, depending on the dose and duration of treatment, it can cause more or less bothersome effects. The most frequently encountered are:

swelling and redness of the face, weight gain,

appearance of bruises,

increased blood pressure, heart damage (congestive heart failure),

excitement, sleep disturbances, euphoria, behavioral disturbances, confusion, convulsions, depressive state on stopping treatment,

bone fragility (osteoporosis, fractures),

modification of certain biological parameters (salt, sugar, potassium) which may require a diet or additional treatment as well as an increase in blood pH.

Other much rarer effects have been observed:

risk of disturbances in the secretion of the adrenal gland,

growth disorder in children,

period disorders,

weakness of muscles

hiccups, stomach or intestinal ulcers, gastrointestinal perforations and bleeding, inflammation of the pancreas,

skin disorders: acne, small red spots (purpura), significant hair growth, delayed healing,

certain forms of glaucoma (increased pressure inside the eye) and cataracts (clouding of the lens).

LOCAL USE

Local risks: infection, lesion, inflammation and calcifications of the joint,

Repeated injections may cause symptoms of hypercorticism (weight gain, swelling) and unbalance diabetes, high blood pressure,

Headaches and hot flashes can occur. They usually go away within a day or two,

Weakening of the skin,

Local and general allergic reactions.

If you notice any side effects not listed in this leaflet, or if any side effects get serious, please tell your doctor or pharmacist.

Keep out of the reach and sight of children.

Diprostene Interactions

SYSTEMIC USE

Not recommended associations

Medicines giving torsades de pointes: astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine.

Use substances which do not have the disadvantage of causing torsades de pointes in the event of hypokalaemia.

CYP3A inhibitors:

Co-administration of CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side effects. The combination should be avoided unless the benefits outweigh the increased risk of systemic side effects from corticosteroids; in this case, patients should be monitored for possible systemic side effects of corticosteroids.

Combinations subject to precautions for use

Acetylsalicylic acid by system and by extrapolation from other salicylates

Decrease in salicylemia during treatment with corticosteroids and risk of salicylate overdose after stopping it, by increased elimination of salicylates by corticosteroids. Adjust the doses of salicylates during the combination and after stopping treatment with corticosteroids.

Antiarrhythmics giving torsades de pointes: amiodarone, brétylium, disopyramide, quinidines, sotalol.

Hypokalaemia is a contributing factor as is bradycardia and a pre-existing long QT space.

Prevent hypokalaemia, correct it if necessary; monitor the QT space. In case of torsade, do not administer antiarrhythmic (electrosystolic training).

Oral anticoagulants

Possible impact of corticosteroid therapy on the metabolism of the oral anticoagulant and on that of coagulation factors.

Haemorrhagic risk specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or in prolonged treatment longer than 10 days.

When the association is justified, strengthen monitoring: biological control on the 8th day, then every 15 days during corticosteroid therapy and after stopping it.

Other hypokalaemic drugs: hypokalaemic diuretics alone or in combination, stimulant laxatives, amphotericin B IV

Increased risk of hypokalaemia by additive effect.

Monitor serum potassium, correct it if necessary, especially in the case of digitalis therapy.

Digital

Hypokalaemia promoting the toxic effects of digitalis.

Monitor serum potassium, correct it if necessary and possibly ECG.

Heparin parenterally

Aggravation by heparin of the hemorrhagic risk specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or in prolonged treatment longer than 10 days.

The association must be justified, strengthen surveillance.

Enzyme inducers: carbamazepine, phenobarbital, phenytoin, primidone, rifabutin, rifampicin

Decrease in plasma levels and the efficacy of corticosteroids by increasing their hepatic metabolism. The consequences are particularly important in Addisonians and in cases of transplantation.

Clinical and biological monitoring, adjustment of the dosage of corticosteroids during the combination and after stopping the enzyme inducer.

Insulin, metformin, sulfonylureas

Elevation of blood sugar with sometimes ketosis (decrease in tolerance to carbohydrates by corticosteroids).

Warn the patient and reinforce blood and urine self-monitoring, especially at the start of treatment. If necessary, adjust the dosage of the antidiabetic medication during treatment with corticosteroids and after stopping it.

Isoniazid (described for prednisolone)

Decreased plasma levels of isoniazid. Mechanism invoked: increased hepatic metabolism of isoniazid and decrease in that of glucocorticoids.

Clinical and biological monitoring.

Associations to take into account

Antihypertensives

Decreased antihypertensive effect (hydrosodium retention of corticosteroids).

Interferon alpha

Risk of inhibition of the action of interferon.

Live attenuated vaccines

Risk of generalized, possibly fatal disease. This risk is increased in subjects already immunocompromised by the underlying disease.

Use an inactivated vaccine when it exists (poliomyelitis).

LOCAL USE

The risks of interactions of glucocorticoids with other drugs are exceptional by local injection under the usual circumstances of use. These risks should be considered in the event of multiple injections (several locations) or repeated in the short term.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Effects on ability to Drive and use machines

This specialty contains an active ingredient that can induce a positive reaction to the tests performed during doping controls.

Warnings and Precautions

Special warnings

This medicine should be taken under strict medical supervision.

INTRAMUSCULAR USE

BEFORE TREATMENT

Tell your doctor in the event of recent vaccination, in the event of digestive ulcer, diseases of the colon, recent surgery on the intestine, diabetes, high blood pressure, infection (especially history of tuberculosis) , liver failure, kidney failure, osteoporosis and myasthenia gravis (muscle disease with muscle fatigue).

Tell your doctor if you are staying in the tropics, subtropics or southern Europe, due to the risk of parasitic disease.

DURING AND AFTER TREATMENT

Avoid contact with people with chickenpox or measles.

Tell your doctor if pain or fever develops after the injection.

Repeated injections risk causing symptoms of hypercorticism (weight gain, swelling, hypertension …) and unbalance diabetes, mental disorders or severe hypertension.

LOCAL USE

In the absence of data concerning the risk of calcification, it is preferable to avoid the administration of a corticosteroid intra-disc.

Notify your doctor in the event of recent vaccination and evolving viral diseases (viral hepatitis, herpes, chickenpox, shingles).

This medicine should be taken under strict medical supervision.

Tell your doctor if pain or fever develops after the injection.

Repeated injections risk causing symptoms of hypercorticism (weight gain, swelling, hypertension …) and unbalance diabetes, mental disorders or severe hypertension.

Precautions for use

In the event of long-term treatment with corticosteroids, your doctor may advise you to follow a diet, in particular low in sodium salt, rapid sugars and high in protein.

Related to excipients

This medicine contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) and may cause allergic reactions with hives and difficulty breathing.

This medicine contains 9 mg / ml of benzyl alcohol. It can cause toxic reactions and allergic reactions in infants and children up to 3 years old.

This medicine contains 5 mg of sodium per pre-filled syringe. The sodium level is less than 1 mmol per pre-filled syringe, that is to say “sodium-free”.

PREGNANCY & BREAST-FEEDING & FERTILITY

Pregnancy

Systemic use:

In animals, experimentation shows a variable teratogenic effect depending on the species.

In humans, there is a placental transfer. However, epidemiological studies have found no teratogenic risk taking steroids during the 1 st quarter.

In chronic diseases requiring treatment throughout pregnancy, a slight delay in intrauterine growth is possible. Neonatal adrenal insufficiency has been observed exceptionally after high dose corticosteroid therapy.

It is justified to observe a period of clinical (weight, diuresis) and biological monitoring of the newborn.

Accordingly, corticosteroids may be prescribed during pregnancy, if needed.

Local use:

The risk of systemic corticosteroids should be considered in the event of multiple injections (several locations) or repeated short term: with systemic corticosteroids, a slight delay in intrauterine growth is possible.

Neonatal adrenal insufficiency has been observed exceptionally after high dose corticosteroid therapy.

Feeding with milk

Systemic use:

In case of treatment in large doses and chronically, breast-feeding is not recommended.

Local use:

In case of treatment in large doses, breast-feeding is not recommended.

What happens if I overdose from Diprostene ?

Not applicable.

What should I do if I miss a dose?

Not applicable.

What happens if you stop taking Diprostene ?

Not applicable.

What is Forms and Composition ?

SHAPES and PRESENTATIONS

Suspension for injection: Box of 1 pre-filled syringe of 1 ml + 2 sterile needles in an individual case (50 8/10 and 25 5/10).

COMPOSITION

p syringe Betamethasone (DCI) 5 mg (as dipropionate: 6.43 mg / ml) Betamethasone (DCI) 2 mg (as disodium phosphate: 2.63 mg / ml)

Excipients:methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), benzyl alcohol, sodium edetate, anhydrous sodium hydrogen phosphate, sodium chloride, polysorbate 80, sodium carmellose, macrogol 4000, concentrated hydrochloric acid, water ppi.

Excipients with known effect: benzyl alcohol (9 mg / ml); sodium (5 mg / ml); Methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216).

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post diprostene injection Uses, Dosage, Side Effects & Precautions appeared first on Drug Online.

from Drug Online https://bit.ly/33p6Vtn via Edrug Online from faculty of medicine https://bit.ly/35xwfjo via Faculty of Medicine

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

colinfitzpatrick · 4 years ago

Text

diprostene injection Uses, Dosage, Side Effects & Precautions

Drug Online

diprostene injection in english >> Generic drug of the Therapeutic class: Anti-inflammatory active ingredients: Betamethasone

what is Diprostene ampoule ?

This medication is a corticosteroid.

It is indicated in cases of allergic rhinitis.

It can be used in local injection in dermatology, rheumatology and ENT.

what is Diprostene injection uses and indication?

SYSTEMIC USE

Seasonal allergic rhinitis after failure of other therapies (systemic antihistamine, intranasal corticosteroid, or oral corticosteroid in short course).

LOCAL USE

This product is indicated in the conditions:

Skin: keloid scars

ENT: intra-sinus irrigation in sinusitis subacute or chronic justifying drainage.

Rheumatologic:

intra-articular injections: inflammatory arthritis, severe arthritis

periarticular injections: tendonitis, bursitis

soft tissue injections: talalgia, carpal tunnel syndrome, Dupuytren’s disease

PRESENTATION (S) AVAILABLE FOR DIPROSTENE

1 pre-filled syringe (s) of 1 ml glass with needle (s)

Diprostene Dosage

The dose to use is determined by your doctor, depending on your weight and the disease being treated.

It is strictly individual.

Diprostene Contraindications

INTRAMUSCULAR USE

Never use DIPROSTENE, suspension for injection in a pre-filled syringe in the following cases:

in premature and term newborns, due to the presence of benzyl alcohol,

most infections,

certain evolving viral diseases (viral hepatitis, herpes, chickenpox, shingles),

certain untreated mental disorders,

vaccination with live vaccines,

allergy to one of the constituents,

coagulation disorders, anticoagulant therapy in progress.

This medication SHOULD NOT GENERALLY BE USED, unless your doctor advises otherwise, in combination with medications which may cause certain heart rhythm disturbances.

LOCAL USE

Never use DIPROSTENE, suspension for injection in a pre-filled syringe in the following cases:

infections,

allergy to one of the constituents,

coagulation disorders, current anticoagulant treatment,

in premature and term newborns, due to the presence of benzyl alcohol.

IN CASE OF DOUBT, IT IS ESSENTIAL TO ASK FOR THE OPINION OF YOUR DOCTOR OR YOUR PHARMACIST.

How To Take Diprostene ?

Method and route of administration

INTRAMUSCULAR INJECTABLE OR LOCAL INJECTION.

Do not inject into the tendons.

Duration of treatment

It is determined by your doctor.

how does Diprostene work?

Pharmacotherapeutic group: corticosteroids for systemic use, not associated, ATC code: H02AB01 .

Physiological glucocorticoids (cortisone and hydrocortisone) are essential metabolic hormones.

Synthetic corticosteroids, including betamethasone, are used primarily for their anti-inflammatory effect.

In high doses, they decrease the immune response. Their metabolic and sodium retention effect is less than that of hydrocortisone.

How To Store Diprostene ?

Keep this medication out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the package after EXP. The expiration date refers to the last day of that month.

Store at a temperature not exceeding 25 ° C and protected from light.

After opening: the product should be used immediately.

Diprostene injection side effects

Like all medicines, DIPROSTENE, suspension for injection in a pre-filled syringe can cause side effects, although not everybody gets them.

INTRAMUSCULAR USE

swelling and redness of the face, weight gain,

appearance of bruises,

increased blood pressure, heart damage (congestive heart failure),

excitement, sleep disturbances, euphoria, behavioral disturbances, confusion, convulsions, depressive state on stopping treatment,

bone fragility (osteoporosis, fractures),

modification of certain biological parameters (salt, sugar, potassium) which may require a diet or additional treatment as well as an increase in blood pH.

Other much rarer effects have been observed:

risk of disturbances in the secretion of the adrenal gland,

growth disorder in children,

period disorders,

weakness of muscles

hiccups, stomach or intestinal ulcers, gastrointestinal perforations and bleeding, inflammation of the pancreas,

skin disorders: acne, small red spots (purpura), significant hair growth, delayed healing,

certain forms of glaucoma (increased pressure inside the eye) and cataracts (clouding of the lens).

LOCAL USE

Local risks: infection, lesion, inflammation and calcifications of the joint,

Repeated injections may cause symptoms of hypercorticism (weight gain, swelling) and unbalance diabetes, high blood pressure,

Headaches and hot flashes can occur. They usually go away within a day or two,

Weakening of the skin,

Local and general allergic reactions.

If you notice any side effects not listed in this leaflet, or if any side effects get serious, please tell your doctor or pharmacist.

Keep out of the reach and sight of children.

Diprostene Interactions

SYSTEMIC USE

Not recommended associations

Medicines giving torsades de pointes: astemizole, bepridil, erythromycin IV, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine.

Use substances which do not have the disadvantage of causing torsades de pointes in the event of hypokalaemia.

CYP3A inhibitors:

Combinations subject to precautions for use

Acetylsalicylic acid by system and by extrapolation from other salicylates

Antiarrhythmics giving torsades de pointes: amiodarone, brétylium, disopyramide, quinidines, sotalol.

Hypokalaemia is a contributing factor as is bradycardia and a pre-existing long QT space.

Prevent hypokalaemia, correct it if necessary; monitor the QT space. In case of torsade, do not administer antiarrhythmic (electrosystolic training).

Oral anticoagulants

Possible impact of corticosteroid therapy on the metabolism of the oral anticoagulant and on that of coagulation factors.

Haemorrhagic risk specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or in prolonged treatment longer than 10 days.

When the association is justified, strengthen monitoring: biological control on the 8th day, then every 15 days during corticosteroid therapy and after stopping it.

Other hypokalaemic drugs: hypokalaemic diuretics alone or in combination, stimulant laxatives, amphotericin B IV

Increased risk of hypokalaemia by additive effect.

Monitor serum potassium, correct it if necessary, especially in the case of digitalis therapy.

Digital

Hypokalaemia promoting the toxic effects of digitalis.

Monitor serum potassium, correct it if necessary and possibly ECG.

Heparin parenterally

Aggravation by heparin of the hemorrhagic risk specific to corticosteroid therapy (digestive mucosa, vascular fragility) at high doses or in prolonged treatment longer than 10 days.

The association must be justified, strengthen surveillance.

Enzyme inducers: carbamazepine, phenobarbital, phenytoin, primidone, rifabutin, rifampicin

Decrease in plasma levels and the efficacy of corticosteroids by increasing their hepatic metabolism. The consequences are particularly important in Addisonians and in cases of transplantation.

Clinical and biological monitoring, adjustment of the dosage of corticosteroids during the combination and after stopping the enzyme inducer.

Insulin, metformin, sulfonylureas

Elevation of blood sugar with sometimes ketosis (decrease in tolerance to carbohydrates by corticosteroids).

Isoniazid (described for prednisolone)

Decreased plasma levels of isoniazid. Mechanism invoked: increased hepatic metabolism of isoniazid and decrease in that of glucocorticoids.

Clinical and biological monitoring.

Associations to take into account

Antihypertensives

Decreased antihypertensive effect (hydrosodium retention of corticosteroids).

Interferon alpha

Risk of inhibition of the action of interferon.

Live attenuated vaccines

Risk of generalized, possibly fatal disease. This risk is increased in subjects already immunocompromised by the underlying disease.

Use an inactivated vaccine when it exists (poliomyelitis).

LOCAL USE

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Effects on ability to Drive and use machines

This specialty contains an active ingredient that can induce a positive reaction to the tests performed during doping controls.

Warnings and Precautions

Special warnings

This medicine should be taken under strict medical supervision.

INTRAMUSCULAR USE

BEFORE TREATMENT

Tell your doctor if you are staying in the tropics, subtropics or southern Europe, due to the risk of parasitic disease.

DURING AND AFTER TREATMENT

Avoid contact with people with chickenpox or measles.

Tell your doctor if pain or fever develops after the injection.

Repeated injections risk causing symptoms of hypercorticism (weight gain, swelling, hypertension …) and unbalance diabetes, mental disorders or severe hypertension.

LOCAL USE

In the absence of data concerning the risk of calcification, it is preferable to avoid the administration of a corticosteroid intra-disc.

Notify your doctor in the event of recent vaccination and evolving viral diseases (viral hepatitis, herpes, chickenpox, shingles).

This medicine should be taken under strict medical supervision.

Tell your doctor if pain or fever develops after the injection.

Repeated injections risk causing symptoms of hypercorticism (weight gain, swelling, hypertension …) and unbalance diabetes, mental disorders or severe hypertension.

Precautions for use

In the event of long-term treatment with corticosteroids, your doctor may advise you to follow a diet, in particular low in sodium salt, rapid sugars and high in protein.

Related to excipients

This medicine contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) and may cause allergic reactions with hives and difficulty breathing.

This medicine contains 9 mg / ml of benzyl alcohol. It can cause toxic reactions and allergic reactions in infants and children up to 3 years old.

This medicine contains 5 mg of sodium per pre-filled syringe. The sodium level is less than 1 mmol per pre-filled syringe, that is to say “sodium-free”.

PREGNANCY & BREAST-FEEDING & FERTILITY

Pregnancy

Systemic use:

In animals, experimentation shows a variable teratogenic effect depending on the species.

In humans, there is a placental transfer. However, epidemiological studies have found no teratogenic risk taking steroids during the 1 st quarter.

It is justified to observe a period of clinical (weight, diuresis) and biological monitoring of the newborn.

Accordingly, corticosteroids may be prescribed during pregnancy, if needed.

Local use:

Neonatal adrenal insufficiency has been observed exceptionally after high dose corticosteroid therapy.

Feeding with milk

Systemic use:

In case of treatment in large doses and chronically, breast-feeding is not recommended.

Local use:

In case of treatment in large doses, breast-feeding is not recommended.

What happens if I overdose from Diprostene ?

Not applicable.

What should I do if I miss a dose?

Not applicable.

What happens if you stop taking Diprostene ?

Not applicable.

What is Forms and Composition ?

SHAPES and PRESENTATIONS

Suspension for injection: Box of 1 pre-filled syringe of 1 ml + 2 sterile needles in an individual case (50 8/10 and 25 5/10).

COMPOSITION

p syringe Betamethasone (DCI) 5 mg (as dipropionate: 6.43 mg / ml) Betamethasone (DCI) 2 mg (as disodium phosphate: 2.63 mg / ml)

Excipients: methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), benzyl alcohol, sodium edetate, anhydrous sodium hydrogen phosphate, sodium chloride, polysorbate 80, sodium carmellose, macrogol 4000, concentrated hydrochloric acid, water ppi.

Excipients with known effect: benzyl alcohol (9 mg / ml); sodium (5 mg / ml); Methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216).

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post diprostene injection Uses, Dosage, Side Effects & Precautions appeared first on Drug Online.

from Drug Online https://bit.ly/33p6Vtn via Edrug Online

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

kisan512posts · 4 years ago

Text

HERG Screening -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021

HERG Screening Industry

Description

Wiseguyreports.Com Adds “HERG Screening -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

hERG Screening Market research report presents an in depth analysis of hERG Screening market. The study emphasizes on both technology and product segments of hERG Screening in biotechnology and pharmaceutical application areas. The report provides essential information including market data, segmentation, market size, key trends, M&A, product developments, industry forecasts, corporate intelligence, and other relevant information. The report lists more than 190 companies that are engaged in hERG Screening services and/or production of hERG screening tools/instruments. A global perspective is presented along with regional analysis covering North America, Europe, Asia-Pacific and Rest of World. Compilation of Worldwide Patents and Research related to hERG Screening is also provided. The hERG Screening market size is analyzed in US Dollars and includes 30 exclusive graphically illustrated exhibits.

OUR NEW SAMPLE HAVE BEEN UPDATED NOW WHICH CORRESPOND IN NEW REPORT SHOWING IMPACT OF COVID-19 ON INDUSTRY

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/30790-herg-screening-market-research-report

Report Highlights

Human Ether-a-go-go Related Gene (hERG gene) (KCNH2) is an encoder of the potassium ion channel that repolarizes IKr current in the heart. It consists of 6 transmembrane domains which are serially numbered from S1-S6. The abnormalities resulting in this channel can either lead to Long QT syndrome (LQT2) or Short QTsyndrome causing loss of function mutations and gain of function mutations respectively. Both of these are considered as potentially fatal cardiac arrhythmia caused due to repolarisation disturbances of the cardiac action potential. Global hERG screening market is projected to grow at 21.82%, compounded annually from 2005 through 2020. hERG Screening has its major role in the pharmaceutical field in drug release process. Some drugs may prolong the QT interval in normal and healthy individuals and result in QT Syndrome. This side effect has promoted majority of pharmaceutical companies to screen compounds for hERG channel activity in early stages of drug discovery and development process. Many companies are developing cell lines such as HEK 293, and CHO to aid in vitro screening for hERG channel activity.

Report by Chapter

I. Scope and Methodology: This chapter provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used.

II. Report Synopsis: Synopsis of the report summarizes the global hERG screening market. The chapter provides market values in US$ for hERG Screening in several geographic regions including the North America, Europe, Asia-Pacific and Rest of World.

III. Market Dynamics: Market Dynamics chapter provides information on global markets for hERG Screening. The chapter includes global market analysis (in US$) by geographic region; analysis of each region; a brief business profile of major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches etc. The section includes key market trends and an industry outlook.

IV. Product/Technology Research: This chapter gives an insight into hERG screening market including definitions, segmentation and applications. The chapter also includes product trends and potential opportunities. Importance of hERG screening in the drug discovery process, technology analysis and technology trends is discussed. Various research activities in the field of hERG Screening finds a mention in this chapter.

V. Corporate Directory: This chapter provides a global region-wise list of 190 plus companies, CROs and academic institutions that are engaged in hERG Screening products and/or services.

VI. Patents Information: This chapter provides a compilation of worldwide patents related to hERG screening products/services/technologies.

Leave a Query @ https://www.wiseguyreports.com/enquiry/30790-herg-screening-market-research-report

Why Buy This Report?

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities

Review and Analyze Global and Regional Markets

Gauge Market Potential for your Products

Identify Competition

Use Market Research for exploring new areas

Acquire Meaningful Guidelines for Strategic Planning

Gear up for Market Entry

Get Actionable Information

Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends

Product (Global and Regional) Market Sizes, Market Shares, Market Trends

Technology Trends

Corporate Intelligence

Key Companies By Sales, Brands, Products

Other Strategic Business Affecting Data

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=30790

Continued…

NOTE : Our final report have added the analysis of the impact of COVID-19 on this industry, Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

0 notes

healthcaretrends-blog · 5 years ago

Text

Electrocardiogram Devices Market 2019: Industry Landscape And Acknowledgement

Electrocardiograph machines are used to measure the electrical activity of a patient’s heart. The electrical activity of the heart is recorded with the help of 12-lead ECGs and 10 electrodes, placed on patient’s limbs and surface of the chest. Furthermore, ECG used to monitor patient’s emergency situation to obtain quick results of heart’s size, position of heart chambers, the rate of the heart, rhythm, and any damage to heart muscles and effect of cardiac drugs. The 12-lead electrocardiogram (ECG) is the most common and widely used in the assessment of cardiovascular disease including cardiac rhythm, detection of myocardial ischemia and infarction, conduction system abnormalities, preexcitation, long QT syndromes, atrial abnormalities, ventricular hypertrophy, pericarditis, and other conditions.

Approval and launch of novel electrocardiogram (ECG) devices and high prevalence of cardiovascular diseases expected to drive global electrocardiogram (ECG) devices market growth

Launch and approval of novel electrocardiogram (ECG) devices in market is expected to drive global electrocardiogram (ECG) devices market growth over the forecast period. For instance, in January 2019, Alphabet Inc.'s health division, Verily received approval from the U.S. Food and Drug Administration (FDA) for Verily’s Study Watch, a wearable medical device that conducts electrocardiograms (ECGs), which measures electrical activity of the heart and can be used to diagnose a number of heart conditions.

Furthermore, high prevalence of cardiovascular disease is expected to be a major factor increasing the demand for electrocardiogram (ECG) devices over the forecast period and supporting global electrocardiogram (ECG) devices market growth. For instance, according to the data published by American Heart Association, in 2018, cardiovascular diseases, listed as the underlying cause of death, accounted for around 836,546 deaths in the U.S. Around, 2,300 deaths are registered in the U.S. from cardiovascular diseases each day, with an average of 1 death every 38 seconds. Around 92.1 million adults in the U.S. are living with some form of cardiovascular diseases or the after-effects of stroke.

Request A Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/2657

According to the same source, coronary heart disease was the leading cause of death (43.8%) in the U.S., followed by stroke (16.8%), heart failure (9.0%), high blood pressure (9.4%), diseases of the arteries (3.1%), and other cardiovascular diseases (17.9%).

The global electrocardiogram (ECG) devices market size was valued at US$ 4.2 Bn in 2018, and is expected to witness a CAGR of 5.8% during the forecast period (2018–2026).

North America electrocardiogram (ECG) devices market is expected to hold dominant position in global electrocardiogram (ECG) devices market, owing to high awareness regarding health and frequent investments by key players in market to launch novel electrocardiogram (ECG) devices in the region. For instance, in 2017, the U.S.-based Cardiac Insight Inc. received the U.S. Food and Drug Administration approval for its novel wearable ECG sensor namely Cardeo Solo. The company has raised around US$ 4.5 million to develop and commercialize its novel wearable. Furthermore, Asia Pacific electrocardiogram (ECG) devices market is expected to be a potential market for key players, owing to increasing ageing population and rising prevalence of cardiovascular disease in key regions of Asia Pacific including China and India. For instance, according to the data published by the World Health Organization (WHO), in China cardiovascular disease is estimated to increase by 50% between 2010 and 2030 based on population aging and growth.

The U.S. Food & Drug Administration (FDA) oversees all the activities associated with food and medical products in the North America region. Under medical devices, all types of medical devices for all types of conditions are considered. Medical devices are classified into three categories such as Class 1, Class 2, and Class 3 medical devices. This classification is risk-based, where risk posed by the device to the patient represents category of the medical device. For instance, class 1 includes devices with lowest risk, whereas class 3 includes devices with greatest risk. Electrocardiogram (ECG) devices come under class II of medical devices.

Key players operating in the global electrocardiogram (ECG) devices market include Cardiac Insight Inc., Koninklijke Philips N.V., General Electric Company, CardioNet Inc., Mindray Medical International Limited, Spacelabs Healthcare (a subsidiary of OSI Systems Inc.), Schiller AG, CompuMed Inc., Nihon Cohden Corporation, and Welch Allyn, Inc.

Click To Reading More On Electrocardiogram (ECG) Devices Market

About Coherent Market Insights:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]

#electrocardiogram devices growth

0 notes